New hope for rare lymphoma: targeted drug plus chemo enters first human tests
NCT ID NCT07278856
First seen Jan 04, 2026 · Last updated May 09, 2026 · Updated 17 times
Summary
This early-phase trial tests whether adding the targeted drug ruxolitinib to standard chemotherapy (CHOP) is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare blood cancer. About 20 adults will take part to find the best dose and watch for side effects. The goal is to control the disease, not cure it, since ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.